Dupixent Cancer Risk: What Patients Should Know

Dupixent (dupilumab) is a biologic medication manufactured by Sanofi and Regeneron that blocks the IL-4 and IL-13 signaling pathways involved in type 2 inflammatory responses. It is FDA-approved for atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and COPD. Post-marketing surveillance data has raised questions about whether immune pathway modulation may be associated with increased malignancy risk in some patients. This guide explains what the current evidence shows, what it doesn't, and what patients should do with this information.

How Dupixent Works and Why Cancer Risk Is a Concern

Dupixent works by blocking the IL-4 receptor alpha subunit, which prevents signaling by both IL-4 and IL-13 — two cytokines that play a central role in type 2 immune responses, the pathway involved in allergic and inflammatory conditions like eczema and asthma. By suppressing this pathway, Dupixent reduces the chronic inflammation driving these conditions.

The concern about cancer risk arises from the immune system's role in tumor surveillance. The IL-4 and IL-13 pathways, among others, are involved in the immune system's ability to recognize and respond to abnormal cells. There is a theoretical basis — supported by some laboratory and epidemiological evidence — that suppressing parts of the immune signaling network over long periods could affect the body's ability to control early malignancies. This is a concern with many immunomodulating biologics, not uniquely with Dupixent, but the specific pathways blocked by Dupixent are ones with known connections to lymphoma biology.

Lymphoma — particularly cutaneous T-cell lymphoma (CTCL) and other lymphoma subtypes — has been reported in Dupixent users in post-marketing data. The FDA Adverse Event Reporting System (FAERS) contains Dupixent-associated lymphoma and other malignancy reports. The challenge in interpreting this data is that atopic dermatitis patients — the largest Dupixent user population — already have an elevated baseline risk of CTCL compared to the general population, making it difficult to attribute individual cases to the medication rather than the underlying condition.

Cutaneous T-Cell Lymphoma: The Specific Signal

Cutaneous T-cell lymphoma (CTCL) has received the most attention in Dupixent post-marketing review. Several published case reports and case series describe patients on Dupixent for atopic dermatitis who were subsequently diagnosed with CTCL. A confounding factor is that early CTCL and severe atopic dermatitis can look very similar clinically — both can present as widespread, treatment-resistant rash — and some cases are believed to represent CTCL that was present before Dupixent treatment but was misdiagnosed as eczema and then became clinically apparent during Dupixent therapy rather than being caused by it.

Regulatory agencies have taken this concern seriously enough to act. In 2023, the European Medicines Agency (EMA) updated Dupixent's product information in Europe to include information about lymphoma cases reported in post-marketing. The FDA has been reviewing the signal in FAERS data and through post-approval safety studies that Sanofi and Regeneron are required to conduct.

Patients currently on Dupixent who notice new skin lesions, lymph node enlargement, unexplained weight loss, or night sweats should report these to their prescribing physician promptly and ask whether dermatology or oncology evaluation is appropriate. These symptoms can have many causes, but in the context of long-term Dupixent use, they warrant evaluation.

Other Malignancy Reports in Post-Marketing Data

Beyond CTCL, FAERS data contains Dupixent-associated reports of other malignancies including solid tumors and other lymphoma subtypes. The FAERS database is a spontaneous reporting system — it captures reports submitted by patients, healthcare providers, and manufacturers, but does not establish causation and is subject to significant underreporting. A report in FAERS means a clinician or patient believed there was a possible connection; it does not mean the connection has been confirmed.

Sanofi and Regeneron's clinical trial data on malignancies has been reviewed in multiple academic analyses. Some analyses have found malignancy rates in Dupixent-treated arms that are numerically higher than placebo, but clinical trials are typically not powered to detect differences in malignancy rates (cancer is rare enough relative to trial sizes that differences often do not reach statistical significance). Observational post-marketing studies with larger populations are better positioned to detect these signals, and several are ongoing.

What the Current Prescribing Information Says

As of early 2026, Dupixent's US prescribing information contains a warning regarding malignancies. The label notes that malignancies, including lymphoma, have been observed in clinical trials and post-marketing experience. It does not carry a Boxed Warning (the FDA's highest warning designation) for malignancy risk, which reflects the current state of evidence — concern without sufficient evidence of a definitive causal relationship to require the most prominent warning level. This labeling status can and does change as post-marketing evidence accumulates.

In litigation, the question of what the label said and when — and whether the warnings kept pace with accumulating post-marketing evidence — is central to failure-to-warn claims. Plaintiffs in pharmaceutical failure-to-warn cases argue that warning language did not adequately reflect available safety signals, resulting in patients and prescribers not receiving the information they needed to make fully informed decisions.

The Litigation Status for Dupixent

As of early 2026, there is no consolidated MDL for Dupixent cancer claims. The litigation is earlier-stage than more developed pharmaceutical MDLs. Individual cases are being evaluated and filed in various courts, and the legal theory (primarily failure to warn and products liability for design) is similar to other biologic drug litigation, but the evidentiary record is still developing as post-marketing studies produce data.

This does not mean legal claims are unavailable. It means that the litigation is at the stage where individual case evaluation and filing are appropriate, and that the developing scientific record makes some claims stronger than others. Cases involving Dupixent use followed by lymphoma diagnosis — particularly CTCL — where the timeline and clinical facts are well-documented, are the cases most likely to receive serious legal evaluation.

What Patients on Dupixent Should Do

For patients currently taking Dupixent, the appropriate response to this information is not to stop the medication without consulting your physician. Dupixent provides significant benefit for many patients with severe eczema and related conditions; the benefit-risk calculation must be made individually with your prescribing doctor, considering how severe your condition is and what alternatives exist. Abrupt discontinuation of Dupixent can cause symptom rebound that is clinically significant.

What is appropriate: discussing the malignancy signal specifically with your prescribing dermatologist or allergist; asking whether monitoring for lymphoma symptoms is warranted given your duration of use; ensuring that any new skin changes, lymph node changes, or systemic symptoms are evaluated promptly and with the Dupixent history in mind; and keeping all treatment records organized for potential future use.

If you used Dupixent and have been diagnosed with cancer — particularly lymphoma, CTCL, or another malignancy — preserving your treatment records and discussing the situation with an attorney who handles pharmaceutical product liability is a reasonable step. Legal evaluation is free and informational; it does not commit you to any course of action.

Related Pages on This Site

• FDA Dupixent warnings and safety updates
• Dupixent vs. other biologics: safety comparison
• Check your eligibility